Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amonafide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 3/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | POLB | P06746 | 4/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | STAT6 | P42226 | 1/20 | 0.64 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.64 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.64 |
| ▸ | HEXA | P06865 | 1/20 | 0.60 |
| ▸ | HEXB | P07686 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | AHR | P35869 | 2/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amonafide SCHEMBL5166034 | 0.96 | FTO (0.84) | FTOCYP2D6MEN1KMT2APOLB | |
| Amonafide SCHEMBL5166747 | 0.91 | FTO (0.84) | FTOCYP2D6MEN1KMT2APOLB | |
| Amonafide SCHEMBL5164837 | 0.91 | FTO (0.84) | FTOCYP2D6MEN1KMT2APOLB | |
| Amonafide SCHEMBL5166271 | 0.91 | FTO (0.76) | FTOCYP2D6MEN1KMT2APOLB | |
| Amonafide SCHEMBL1565520 | 0.90 | FTO (0.86) | FTOCYP2D6MEN1KMT2APOLB | |
| Amonafide SCHEMBL6255345 | 0.90 | FTO (1.00) | FTOCYP2D6MEN1KMT2APOLB | |
| Amonafide SCHEMBL29352008 | 0.90 | FTO (1.00) | FTOCYP2D6MEN1KMT2APOLB | |
| Amonafide SCHEMBL27226 | 0.90 | FTO (1.00) | FTOCYP2D6MEN1KMT2APOLB | |
| Amonafide SCHEMBL5165675 | 0.89 | FTO (0.84) | FTOCYP2D6MEN1KMT2APOLB | |
| Amonafide SCHEMBL1049714 | 0.89 | FTO (0.97) | FTOCYP2D6MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499595-B1 | AMONAFIDE SALTS | XANTHUS LIFE SCIENCES INC (CA) | 2007-04-11 | — | — | EP | claimed |
| US-20050113579-A1 | Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof | CHEMGENEX THERAPEUTICS, INC. | 2005-05-26 | — | — | US | claimed |
| EP-1499595-A1 | AMONAFIDE SALTS | Xanthus Life Sciences, Inc. (CA) | 2005-01-26 | — | — | EP | claimed |
| US-20040132763-A1 | Amonafide salts | XANTHUS LIFE SCIENCES, INC. | 2004-07-08 | — | — | US | claimed |
| WO-2003089415-A1 | AMONAFIDE SALTS | XANTHUS LIFE SCIENCES, INC. (CA) | 2003-10-30 | — | — | WO | claimed |
| EP-1499595-B1 | AMONAFIDE SALTS | XANTHUS LIFE SCIENCES INC (CA) | 2007-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132763-A1 | Amonafide salts | OR10J3, NR4A1, OGFR | FTO 974/4885CYP2D6 135/4885MEN1 2884/4885 |
| US-20050113579-A1 | Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof | NME4, MFN2, NDUFAB1 | FTO 1262/4885CYP2D6 103/4885MEN1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.